Candel Therapeutics, Inc.

“By 2025, clinical trials will undergo transformative advancements, driven by innovation, patient-centricity, and regulatory evolution.” So said Scott Schliebner , vice president and global head, dru

Many public biopharmaceutical companies have taken advantage of the ongoing capital markets recovery in 2024 by raising money through follow-on public offerings (FOPOs) after announcing key research a

Candel Therapeutics has secured a much-needed win for its herpes simplex-based immunotherapy, CAN-2409. Phase III results show it helped improve disease-free survival for men with localized prostate c

Promising early results from novel cancer immunotherapies have been behind the some of the most meteoric share price increases of 2024 so far. An analysis of stock movements from Evaluate Pharma’s dat